View Older Stories View More Recent Stories
-
Lumos Pharma, Inc. (LUMO) Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma, Inc. (LUMO) Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Lumos Pharma (LUMO) issues new guidance concerning the Phase 2 OraGrowtH210 Trial of LUM-201 in PGHD
-
Lumos Pharma Announces Clinical Updates
-
Lumos Pharma Announces Clinical Updates
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Lumos Pharma (LUMO) Announces Retirement of Carl Langren and Names Lori Lawley CFO in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma (LUMO) Says Data Supporting Use of Predictive Enrichment Markers for its LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Lumos Pharma Announces Changes to its Board of Directors
-
Lumos Pharma Announces Changes to its Board of Directors
-
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
-
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
-
Lumos Pharma to Participate in December Investor Conferences
-
Lumos Pharma to Participate in December Investor Conferences
-
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
